Truist Financial Cuts Hims & Hers Health (NYSE:HIMS) Price Target to $37.00

Hims & Hers Health (NYSE:HIMS) had its price target trimmed by Truist Financial from $48.00 to $37.00 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

HIMS has been the subject of a number of other reports. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. TD Cowen lowered Hims & Hers Health from a “buy” rating to a “hold” rating and decreased their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Morgan Stanley reaffirmed an “equal weight” rating and set a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Stock Up 3.1%

NYSE:HIMS opened at $43.4750 on Monday. The firm has a market capitalization of $9.83 billion, a PE ratio of 54.34, a price-to-earnings-growth ratio of 2.85 and a beta of 2.08. The stock has a 50 day moving average of $52.18 and a 200-day moving average of $45.73. Hims & Hers Health has a 52 week low of $13.47 and a 52 week high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same period last year, the company posted $0.06 earnings per share. The firm’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling

In other news, insider Michael Chi sold 2,100 shares of the stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the sale, the insider owned 278,654 shares in the company, valued at approximately $16,028,178.08. This represents a 0.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the sale, the chief executive officer owned 89,521 shares of the company’s stock, valued at $4,033,816.26. This trade represents a 58.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,396,090 shares of company stock worth $71,927,627 over the last quarter. 13.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently modified their holdings of HIMS. Envestnet Asset Management Inc. lifted its holdings in shares of Hims & Hers Health by 139.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company’s stock valued at $1,903,000 after purchasing an additional 45,791 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at $18,048,000. Barclays PLC lifted its holdings in shares of Hims & Hers Health by 48.3% in the fourth quarter. Barclays PLC now owns 457,246 shares of the company’s stock valued at $11,056,000 after purchasing an additional 148,883 shares in the last quarter. Mariner LLC lifted its holdings in shares of Hims & Hers Health by 77.4% in the fourth quarter. Mariner LLC now owns 19,943 shares of the company’s stock valued at $482,000 after purchasing an additional 8,699 shares in the last quarter. Finally, Guggenheim Capital LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at $274,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.